TELK Share Price

Open 5.10 Change Price %
High 5.50 1 Day 0.00 0.00
Low 5.10 1 Week 0.00 0.00
Close 5.50 1 Month 0.00 0.00
Volume 841 1 Year 0.00 0.00
52 Week High 117.42
52 Week Low 79.95
TELK Important Levels
Resistance 2 5.87
Resistance 1 5.72
Pivot 5.37
Support 1 5.28
Support 2 5.13
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.45 7.29%
MU 20.45 7.29%
MU 20.45 7.29%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ANTH 2.03 38.10%
EMKR 8.45 31.01%
MBLX 0.32 28.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 8.00 23.08%
ATEA 1.95 21.88%
ATEA 1.95 21.88%
More..
NASDAQ USA Top Losers Stocks
DSTI 0.00 -100.00%
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Telik, Inc. (NASDAQ: TELK)

TELK Technical Analysis 5
As on 9th Oct 2014 TELK Share Price closed @ 5.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.34 & Strong Buy for SHORT-TERM with Stoploss of 1.32 we also expect STOCK to react on Following IMPORTANT LEVELS.
TELK Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
TELK Other Details
Segment EQ
Market Capital 3358708.75
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.telik.com
TELK Address
TELK
2100 Geng Road
Suite 102
Palo Alto, CA 94303
United States
Phone: 650-845-7700
Fax: 650-845-7800
Interactive Technical Analysis Chart Telik, Inc. ( TELK NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Telik, Inc.
TELK Business Profile
Telik, Inc. (Telik) is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�s drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells. In June 2011, the Company initiated a Phase II clinical trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. As of December 31, 2011, Telik had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphom and multiple myeloma.